3 N Effects Towards R & D of Selected Pharmaceutical Companies in India
| dc.contributor.author | DR.KHUSHBU PATEL | |
| dc.contributor.author | DR.VIGNA OZA | |
| dc.date.accessioned | 2026-06-25T08:34:43Z | |
| dc.date.issued | 2024-03-05 | |
| dc.description | The pharmaceutical business creates many novel medications with beneficial health effects each year. The cost of many of those medications means that both the public and private sectors must contribute more to healthcare. Lawmakers have considered bills that would reduce prescription drug costs as well as government drug spending. These rules would likely lessen the industry's incentive to produce new medications. The Congressional Budget Office evaluates funding trends for research and development (R&D)and new drug releases in this study. The CBO also considers variables such as anticipated global drug sales, the expense of creating a new medication, and federal laws that affect the availability of new medications, the need for drug therapy, or both. The amount that pharmaceutical businesses invest in R&D may be impacted by several factors. | |
| dc.description.abstract | These days, technological innovation and marketing prowess are crucial tools used by businesses to strengthen their competitive edge. Within the pharmaceutical industry, new medical breakthroughs are mostly created and introduced through research and development, or R&D. Each year, life science businesses invest billions of dollars in research and development; because to the pandemic, this sum has surged recently. Pharma R&D trends like virtual engagement and insights management are already having an impact on how this crucial role will develop and evolve in the future. This article examined the link between R&D expenses and financial characteristics of a selected pharmaceutical business in India using samples of listed pharmaceutical companies over the test period of 2018-2022. In this research study, we employed ratio analysis and ANOVA Analysis to determine the influence of R&D expenses. The results show that these expenses have a substantial negative link with net profit, net sales, and net worth. | |
| dc.identifier.citation | http://www.semcom.ac.in/SMTRHome.php | |
| dc.identifier.uri | http://www.semcom.ac.in/SMTRHome.php | |
| dc.identifier.uri | http://160.160.1.15:4000/handle/123456789/509 | |
| dc.language.iso | en | |
| dc.publisher | Charutar Vidya Mandal (Estd.1945) | |
| dc.subject | Research & Development | |
| dc.subject | Pharmaceutical Company | |
| dc.subject | Net profit | |
| dc.subject | Net Sales | |
| dc.subject | Net Worth. | |
| dc.title | 3 N Effects Towards R & D of Selected Pharmaceutical Companies in India | |
| dc.type | Article |